Eyepoint, Inc. (EYPT) Stock Price & Analysis
Eyepoint, Inc. (EYPT) fell 2.25% to USD 12.19 as of July 25, 2026 at 06:11 UTC, according to Nexqual real-time market data.
EYPT last closed at USD 12.47; the session ranged USD 12.06–12.45 on volume of 1,444,400 shares. Market capitalization is $1.02B, with a 52-week range of USD 9.4–19.11 (NGM). Source: Nexqual, July 25, 2026 at 06:11 UTC.
Key Statistics (as of July 25, 2026 at 06:11 UTC)
| Price | USD 12.19 |
|---|---|
| Change | ▼ 2.25% (down) |
| Previous Close | USD 12.47 |
| Open | USD 12.45 |
| Day Range | USD 12.06 – 12.45 |
| 52-Week Range | USD 9.4 – 19.11 |
| Volume | 1,444,400 shares |
| Market Cap | $1.02B |
| Exchange | NGM |
Technical Analysis (EYPT)
Nexqual's technical model rates EYPT "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.36 (neutral) |
| vs SMA50 | Below (USD 13.16) |
| MACD | -0.23 (negative) |
Analyst Ratings (EYPT)
Wall Street analysts rate EYPT "Strong Buy" based on 14 analysts, with a mean price target of USD 40.29 (range USD 20–68), per Nexqual as of July 25, 2026 at 06:11 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 40.29 |
| High Target | USD 68 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 14 / 0 / 0 |
Earnings (EYPT)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.96 |
| Revenue Estimate | $372,290 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.99 vs est -0.81 ▼ miss |
| 2025-12-31 | USD -0.81 vs est -0.75 ▼ miss |
| 2025-09-30 | USD -0.85 vs est -0.77 ▼ miss |
| 2025-06-30 | USD -0.85 vs est -0.8 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Financials & Fundamentals (EYPT)
| Total Revenue | $7.61M |
|---|---|
| Revenue Growth (YoY) | +161.70% |
| Gross Margin | +0.00% |
| Operating Margin | -450.65% |
| Profit Margin | +0.00% |
| ROE | -102.71% |
| Debt / Equity | 46.82 |
| Current Ratio | 6.66 |
| Total Cash | $45.26M |
| Total Debt | $17.62M |
| Free Cash Flow | $-168.72M |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Financial Health Score (EYPT)
Nexqual rates Eyepoint, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:11 UTC.
| Growth | Critical — Revenue -28% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $45M cash vs $18M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$169M, burning cash |
| Efficiency | Critical — ROE -103%, ROA -54.1% |
Ownership (EYPT)
| Insider Ownership | +3.68% |
|---|---|
| Institutional Ownership | +111.95% |
| Shares Outstanding | 83.84M |
| Float | 70.47M |
| Short % of Float | +20.65% |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Leadership (EYPT)
Eyepoint, Inc. is led by Jay S. Duker (age 66), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:11 UTC.
| President, CEO & Director | Jay S. Duker (age 66) |
|---|---|
| Executive VP & CFO | George O. Elston (age 60) |
| Chief Scientific Officer | Marcia Sellos-Moura |
| Senior Vice President | David Scott Jones M.A. (age 57) |
Major Backers & Investors (EYPT)
Notable institutional backers of Eyepoint, Inc. include Federated Hermes, Inc., Suvretta Capital Management, LLC, Cormorant Asset Management, LP, according to Nexqual as of July 25, 2026 at 06:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Federated Hermes, Inc. | 12.43% |
| Suvretta Capital Management, LLC | 9.9% |
| Cormorant Asset Management, LP | 9.86% |
| Franklin Resources, Inc. | 6.02% |
| Janus Henderson Group PLC | 4.3% |
| Adage Capital Partners GP L.L.C. | 3.94% |
| Paradigm Biocapital Advisors LP | 3.75% |
| Commodore Capital Lp | 3.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.77% |
| Vanguard Group | 8.39% |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
From Eyepoint, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
- The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
- Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME).
- The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OCUL | Ocular Therapeutix, Inc. | USD 8.51 | ▼ 0.93% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.72 | ▲ 0.54% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 10.07 | ▼ 8.12% |
| SLDB | Solid Biosciences Inc. | USD 7.83 | ▼ 3.33% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.52 | ▼ 10.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:11 UTC. This page is informational and not investment advice.